EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda
  
J&J building
Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23. • Source: Shutterstock

More from Scrip

More from Therapy Areas